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Abstract
Background: Some studies have reported associations between five uncoupling protein (UCP) 1–3 polymorphisms and type
2 diabetes mellitus (T2DM). However, other studies have failed to confirm the associations. This paper describes a case-
control study and a meta-analysis conducted to attempt to determine whether the following polymorphisms are associated
with T2DM: -3826A/G (UCP1); -866G/A, Ala55Val and Ins/Del (UCP2) and -55C/T (UCP3).
Methods: The case-control study enrolled 981 T2DM patients and 534 nondiabetic subjects, all of European ancestry. A
literature search was run to identify all studies that investigated associations between UCP1–3 polymorphisms and T2DM.
Pooled odds ratios (OR) were calculated for allele contrast, additive, recessive, dominant and co-dominant inheritance
models. Sensitivity analyses were performed after stratification by ethnicity.
Results: In the case-control study the frequencies of the UCP polymorphisms did not differ significantly between T2DM and
nondiabetic groups (P.0.05). Twenty-three studies were eligible for the meta-analysis. Meta-analysis results showed that
the Ala55Val polymorphism was associated with T2DM under a dominant model (OR = 1.27, 95% CI 1.03–1.57); while the -
55C/T polymorphism was associated with this disease in almost all genetic models: allele contrast (OR = 1.17, 95% CI 1.02–
1.34), additive (OR = 1.32, 95% CI 1.01–1.72) and dominant (OR = 1.18, 95% CI 1.02–1.37). However, after stratification by
ethnicity, the UCP2 55Val and UCP3 -55C/T alleles remained associated with T2DM only in Asians (OR = 1.25, 95% CI 1.02–
1.51 and OR = 1.22, 95% CI 1.04–1.44, respectively; allele contrast model). No significant association of the -3826A/G, -866G/
A and Ins/Del polymorphisms with T2DM was observed.
Conclusions: In our case-control study of people with European ancestry we were not able to demonstrate any association
between the UCP polymorphisms and T2DM; however, our meta-analysis detected a significant association between the
UCP2 Ala55Val and UCP3 -55C/T polymorphisms and increased susceptibility for T2DM in Asians.
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Introduction
Diabetes mellitus (DM) has elevated prevalence, morbidity and
mortality rates and the social and economic repercussions of its
chronic complications compromise both the quality of life and
productivity of those affected, making it a serious public health
problem. Type 2 DM (T2DM) accounts for 90–95% of DM cases
worldwide and usually occurs in obese subjects over 40 years of
age. It is characterized by chronic hyperglycaemia caused by a
combination of insulin resistance and inadequate compensatory
insulin secretion [1].
Type 2 DM is a multifactorial condition and susceptibility to it is
determined by the combined effects of multiple genetic and
environmental factors [2]. The most likely explanation for the
dramatic increase in T2DM prevalence observed over the past two
decades is changing patterns of diet and physical activity.
However, it is believed that these environmental changes may
only lead to T2DM in the presence of a permissive genetic
background [2]. Great effort has therefore been exerted in
attempts to identify genes associated with T2DM and a number
of studies have focused on genes related to energy expenditure,
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such as those encoding the mitochondrial uncoupling proteins
(UCPs) [3,4,5,6].
Uncoupling proteins 1, 2 and 3 are members of an anion-carrier
protein family located in the mitochondrial inner membrane [7].
These proteins share structural similarities, but have different
tissue expression in mammals [8]. The original UCP, UCP1, is
mainly expressed in brown adipose tissue [6,9]. It was recently
shown that under certain pathological conditions, such as
hyperglycaemia, UCP1 is also expressed in skeletal muscle, white
adipose tissue, retinal cells and pancreatic beta cells [8,10,11].
Uncoupling protein 2 is distributed across a wide range of tissue
and cell types, whereas UCP3 is mainly restricted to skeletal
muscle [5,9].
Over the last few years, several studies have shown that UCPs
reduce metabolic efficiency by dissociating substrate oxidation in
mitochondria from ATP synthesis by the mitochondrial respira-
tory chain. This is thought to be accomplished by promoting net
translocation of protons from intermembrane space, across inner
mitochondrial membrane, to mitochondrial matrix, thereby
dissipating the potential energy available for ATP synthesis and
consequently reducing ATP production [12]. This uncoupling
effect enables homologue-specific and tissue-specific functions such
as thermogenesis (UCP1), regulation of free fatty acid (FFA)
metabolism and transport (UCP2 and UCP3), attenuation of
production of reactive oxygen species (ROS) by mitochondria
(UCP1–3), and regulation of insulin secretion by pancreatic beta
cells (UCP2), all of which are mechanisms associated with T2DM
pathogenesis [5,7,9,12].
Therefore, the relationship between UCP loci and susceptibility
to T2DM has been investigated in a number of genetic studies and
particular attention has been focused on the -3826A/G
(rs1800592) polymorphism in the promoter region of the UCP1
gene, the -866G/A polymorphism (rs659366) in the promoter
region, the Ala55Val (C/T; rs660339) polymorphism in exon 4
and the Ins/Del polymorphism, which is an insertion/deletion of
45 bp in the 39 untranslated region (39UTR) of exon 8 of the
UCP2 gene, and the -55C/T (rs1800849) polymorphism in the
promoter region of the UCP3 gene. The results of these studies are
not uniform. While some of them have demonstrated associations
between one or more of these polymorphisms and T2DM or
related characteristics such as obesity, others were unable to detect
any associations between the polymorphisms and such character-
istics (reviewed in [3,4,5,6,9]).
Considering that T2DM is caused by interactions between a
large number of environmental and genetic factors, it is not
unexpected that some genetic association studies will fail to
confirm associations with the disease even if they actually exist.
Indeed, T2DM has been described as a ‘‘geneticist’s nightmare’’
and it may be the case that it will be necessary to study huge
numbers of patients in order to elucidate the associations between
even a single polymorphism and the disease [13]. Therefore, as
part of the ongoing effort to examine the hypothesis that UCP
polymorphisms are associated with T2DM risk, we performed a
case-control study of Brazilian Caucasian subjects followed by a
meta-analysis of the literature on the subject.
Materials and Methods
Case-control study
Ethical approval of the research protocol. The informa-
tion obtained from the study did not influence patients’ diagnosis
or treatment. The study protocol was approved by Ethic
Committee in Research from Hospital de Clı́nicas de Porto
Alegre and all patients and nondiabetic subjects provided
informed consent in writing. All clinical investigation has been
conducted according to the principles expressed in the Declaration
of Helsinki.
Type 2 Diabetes Mellitus population. The sample popu-
lation comprised 981 unrelated T2DM patients participating in a
multicenter study that began recruiting patients in Southern Brazil
in 2002. That project was designed to study risk factors for DM
and its chronic complications. It initially included four centres in
teaching hospitals located in the Brazilian state of Rio Grande do
Sul, specifically the Grupo Hospitalar Conceição, the Hospital São
Vicente de Paula, the Hospital Universitário de Rio Grande, and
the Hospital de Clı́nicas de Porto Alegre. A detailed description of
that study can be found elsewhere [14]. Type 2 DM was diagnosed
according to the American Diabetes Association criteria [1].
All patients had European ancestry (mostly of Portuguese,
Spanish, Italian and German descent). Ethnicity was defined by
self-report. A standard questionnaire was used to collect informa-
tion on age, age at DM diagnosis and drug treatment and all
patients underwent physical examination and laboratory tests.
They were weighed barefoot, wearing light outdoor clothing and
their height was measured. Body mass index (BMI) was calculated
as weight (kg)/height (meters2). Blood pressure (BP) was measured
twice, in the sitting position, after a 5-min rest, and with a 2-min
interval between measurements, using a mercury sphygmoma-
nometer (Korotkoff phases I and V). The means of both
measurements were used to calculate systolic and diastolic BP.
Arterial hypertension was defined as BP $140/90 mm Hg, but
patients on antihypertensive drugs were defined as hypertense
irrespective of BP at the time of assessment.
The characteristics of the T2DM patients analyzed in this study
were as follows: mean age was 59.52610.63 years, mean T2DM
duration was 13.3369.08 years, mean age at T2DM diagnosis was
46.7611.6 years, mean glycated haemoglobin (GHb) was
7.1862.05%, and mean BMI was 28.8465.39 kg/m2. Males
comprised 47.4% of the sample, and 72.2% of all patients had
arterial hypertension.
Nondiabetic sample. The control group contained 534
nondiabetic volunteers attending the blood donation facility at
the Hospital de Clı́nicas de Porto Alegre (Porto Alegre, Brazil)
(mean age = 44.067.8 years; males = 55.0%). None of these
people had DM or a family history of the disease. All of them
had European ancestry.
Laboratory analyses. Serum samples were collected for
laboratory testing after 12 hours fasting. Glucose levels were
determined using the glucose oxidase method; GHb was assayed
using an ion-exchange HPLC procedure (Merck-Hitachi L-9100
analyzer, Merck, Darmstadt, Germany; reference range: 4.7–
6.0%); and total plasma cholesterol, HDL-C, and triglycerides
were all tested using enzymatic methods. The fraction of LDL
cholesterol was calculated using the Friedewald equation. The
nondiabetic subjects did not undergo any of these laboratory tests.
Genotyping. DNA was extracted from peripheral blood
leukocytes using a standardized salting-out procedure. The -
866G/A (rs659366) polymorphism in the promoter region of the
UCP2 gene was detected by digesting polymerase chain reaction
(PCR) products with the restriction enzyme MluI (Invitrogen Life
Technologies, Inc., San Diego, CA, USA) as previously described
[15]. Digestion fragments were resolved on 2% agarose gels
containing GelRedTM Nucleic Acid Gel Stain (Biotium Inc., CA,
USA) and viewed under ultraviolet light. A DNA sample with a
known genotype (identified by sequencing) was used as a positive
control to evaluate the completeness of PCR product digestion.
The 45 bp Ins/Del polymorphism in the 39UTR region of exon 8
of the UCP2 gene was detected by PCR using primers that have
UCP1–3 Polymorphisms, Meta-Analysis and Diabetes
PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e54259
been described elsewhere [16]. The primers amplified products of
457 bp (insertion allele) or 412 bp (deletion allele), which were
then resolved on 2% agarose gels stained with GelRedTM Nucleic
Acid Gel Stain and viewed under ultraviolet light [17]. Genotypes
of the -866G/A and Ins/Del polymorphisms were recorded using
the ImageMaster System VDS (GE HealthCare, London, UK).
Primers and probes contained in the 406 Human Custom
TaqMan Genotyping Assay (Assays-By-Design Service; Life
Technologies, Foster City, CA; USA) were used to genotype the
Ala55Val (C/T) polymorphism (rs660339) in exon 4 of the UCP2
gene, the -3826A/G (rs1800592) polymorphism in the promoter
region of the UCP1 gene, and the -55C/T (rs1800849) polymor-
phism in the promoter region of the UCP3 gene. Reactions were
conducted in 96-well plates, in a 5 ml total reaction volume using
2 ng of genomic DNA, TaqMan Genotyping Master Mix 16 (Life
Technologies), and Custom TaqMan Genotyping Assay 16
specific for each polymorphism (Life Technologies). The plates
were then placed in a real-time PCR thermal cycler (7500 Fast
Real Time PCR System; Life Technologies) and heated for
10 minutes at 95uC, followed by 50 cycles of 95uC for 15 seconds
and 63uC for 1 minute. Fluorescence data files from each plate
were analyzed using automated allele-calling software (System
Sequence Detection v.1.4; Life Technologies).
Genotyping success rates were more than 95% for all
polymorphisms and the calculated error rate based on PCR
duplicates was less than 3%.
Statistical analyses for the case-control study. Allele
frequencies were determined by gene counting and departures
from the Hardy-Weinberg equilibrium (HWE) were verified using
goodness-of-fitness x2 tests. Allele and genotype frequencies were
compared between groups using the x2 test. Logistic regression
analyses were performed to assess independent associations
between the UCP polymorphisms and T2DM, after adjustment
for age and gender. Two-tailed P values,0.05 were considered
statistically significant. Statistical analyses were conducted using
SPSS version 18.0 (SPSS, Chicago, IL, USA).
Meta-analysis
Search strategy and eligibility criteria. This study was
designed and described in accordance with current guidelines
[18,19]. PubMed and Embase were searched systemically to
identify all available genetic studies of associations between T2DM
and the most-often studied polymorphisms of UCP genes (UCP1 -
3826A/G, UCP2 -866G/A, UCP2 Ala55Val, UCP2 Ins/Del and
UCP3 -55C/T) using the following medical subject headings
(MeSH): ‘‘Diabetes mellitus, type 2’’ AND (‘‘mitochondrial
uncoupling protein’’ OR ‘‘SLC25A27 protein, human’’ OR
‘‘mitochondrial uncoupling protein 2’’ OR ‘‘mitochondrial
uncoupling protein 3’’) AND (‘‘mutation’’ OR ‘‘frameshift
mutation’’ OR ‘‘germ-line mutation’’ OR ‘‘INDEL mutation’’
OR ‘‘mutation, missense’’ OR ‘‘point mutation’’ OR ‘‘codon,
nonsense’’ OR ‘‘sequence deletion’’ OR ‘‘polymorphism, genetic’’
OR ‘‘polymorphism, single nucleotide’’ OR ‘‘polymorphism,
restriction fragment length’’). The search was limited to human
and English or Spanish language papers and was completed on
August 24, 2012. All of the articles identified were also searched
manually to identify any other relevant citations.
Two investigators (D.A.S and A.P.B.) independently reviewed
the titles and abstracts of all articles selected in order to evaluate
whether the studies were eligible for inclusion in the meta-analysis.
Disagreements were resolved by discussion between them and
when necessary a third reviewer (D.C.) was consulted. Where
abstracts did not provide enough information regarding the
inclusion and exclusion criteria, the full text of the article was
retrieved for evaluation. We included observational studies (case-
control or cross-sectional designs) that compared one or more of
the UCP polymorphisms in question between a known number of
T2DM patients and nondiabetic subjects. Studies were excluded
from the analysis if the genotype distributions in control group
deviated from those predicted by the HWE, if they did not have
sufficient data to estimate an OR with 95% CI or if they did not
employ validated genotyping methods. If data were duplicated and
had been published more than once, the most complete study was
chosen.
Data extraction and quality control assessment. Data
were independently extracted by two investigators (B.M.S. and
L.A.B.) using a standardized abstraction form, and consensus was
sought in all extracted items. When consensus could not be
reached, differences in data extraction were resolved by a third
reviewer (D.C.) and by referencing the original publication. The
information extracted from each individual study was as follows:
name of first author, publication year, ethnicity and number of
subjects in case and control groups, age, gender, BMI, genotype
and allele frequencies in case and control subjects and OR (95%
CI).
Two investigators (B.M.S and L.A.B.) independently assessed
the quality of each eligible study using the Newcastle-Ottawa Scale
(NOS) for assessing quality of case-control studies in meta-analysis
[20]. The NOS contains eight items, categorized into three
dimensions including selection, comparability, and exposure. For
each item a series of response options is provided. A star system is
used to allow a semi-quantitative assessment of study quality, such
that the highest quality studies are awarded a maximum of one
star for each item, with the exception of the item related to
comparability, which allows two stars to be assigned. The total
NOS score therefore ranges from zero to nine stars [21].
Statistical analysis for meta-analyses. Control subjects’
genotype distributions were tested for conformity with HWE using
a goodness-of-fitness x2 test. Gene-disease associations were
measured using OR (95% CI) estimation based on the following
genetic inheritance models: (1) allele contrast; (2) additive model;
(3) recessive model; (4) dominant model and (4) co-dominant
model [22,23].
Heterogeneity was tested using a x2-based Cochran’s Q statistic
and inconsistency was assessed with the I2 metric. Heterogeneity
was considered statistically significant at P,0.10 for the Q statistic
and I2.50% for the I2 metric statistic. Where significant
heterogeneity was detected, the DerSimonian and Laird random
effect model (REM) was used to calculate OR (95% CI) for each
individual study and for the pooled effect; where heterogeneity was
not significant, the fixed effect model (FEM) was used for this
calculation [24,25].
Meta-regression and sensitivity analyses were carried out to
identify key studies with a substantial impact on inter-study
heterogeneity. The factors investigated by meta-regression were
age, gender, BMI and ethnicity. Sensitivity analyses were
performed after stratifying the studies by ethnicity given that the
UCP polymorphisms show different frequencies in different ethnic
groups.
Risk of publication bias was assessed using funnel plot graphics,
analyzed both visually and with the Begg and Egger test [26]. The
significance of the intercept was determined by the t test, as
proposed by Egger, with P,0.10 considered indicative of
statistically significant publication bias. All statistical analyses were
performed using Stata 11.0 software (StataCorp, College Station,
TX, USA).
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Results
Case-control study
Table 1 lists the genotype and allele frequencies of the UCP1 -
3826A/G, UCP2 -866G/A, UCP2 Ala55Val, UCP2 Ins/Del and
UCP3 -55C/T polymorphisms. The genotype frequencies of all
polymorphisms were in agreement with those predicted by the
HWE in non-diabetic subjects (P.0.05) and did not differ
significantly between T2DM and nondiabetic groups (Table 1).
These results did not change after adjustment for age and gender
(Table 1). Furthermore, the allele frequencies of these polymor-
phisms were similar in T2DM patients and nondiabetic subjects
(Table 1). It is worth mentioning that the frequencies of these five
UCP polymorphisms also did not differ statistically when assuming
dominant, recessive, additive or co-dominant models of inheri-
tance (P.0.05).
Meta-analysis
Literature search and characteristics of eligible
studies. Figure 1 is a flow diagram illustrating the strategy
used to identify and select studies for inclusion in the meta-
analysis. A total of 582 potentially relevant citations were retrieved
by searching the electronic databases and 539 of them were
excluded during the review of titles and abstracts. Forty-three
articles therefore appeared to be eligible at this point and their full
texts were evaluated. However, after reading the full text, another
21 studies were excluded because of missing information or
ineligible study designs or because they genotyped other UCP
polymorphisms, but not the ones of interest here (Figure 1). A
total of 23 articles fulfilled the eligibility criteria and were included
in the meta-analyses: 22 that had been identified through the
database searches [15,27,28,29,30,31,32,33,34,35,36,37,38,39,40,
41,42,43,44,45,46] in addition to the case-control study we
describe above, which was also included in the analysis.
Table 1. Genotype and allele distributions of UCP polymorphisms in type 2 diabetes patients and non-diabetic subjects.
UCP Polymorphisms Cases Controls Unadjusted P* Adjusted OR, 95% CI/P{
UCP1 -3826A/G n = 981 n = 534
A/A 489 (49.9) 263 (49.3) 0.694 1
A/G 370 (37.7) 211 (39.5) 1.018 (0.696–1.489)/0.926
G/G 122 (12.4) 60 (11.2) 0.984 (0.554–1.748)/0.956
A 0.687 0.690 0.510 -
G 0.313 0.310
UCP2 -866G/A n = 778 n = 435
G/G 272 (35.0) 152 (34.9) 0.950 1
G/A 372 (47.8) 211 (48.5) 1.136 (0.760–1.697)/0.534
A/A 134 (17.2) 72 (16.6) 1.405 (0.807–2.444)/0.229
G 0.589 0.592 0.909 -
A 0.411 0.408
UCP2 Ala55Val n = 784 n = 453
Ala/Ala 265 (33.8) 142 (31.3) 0.539 1
Ala/Val 371 (47.3) 229 (50.6) 0.871 (0.578–1.313)/0.510
Val/Val 148 (18.9) 82 (18.1) 1.116 (0.650–1.917)/0.691
Ala 0.575 0.566 0.716 -
Val 0.425 0.434
UCP2 Ins/Del n = 779 n = 461
Del/Del 379 (48.7) 226 (49.0) 0.699 1
Ins/Del 314 (40.3) 191 (41.4) 0.880 (0.598–1.295)/0.516
Ins/Ins 86 (11.0) 44 (9.6) 1.387 (0.734–2.621)/0.313
Del 0.688 0.697 0.642 -
Ins 0.312 0.303
UCP3 -55C/T n = 822 n = 351
C/C 559 (68.0) 239 (68.1) 0.988 1
C/T 231 (28.1) 99 (28.2) 0.841 (0.561–1.260)/0.400
T/T 32 (3.9) 13 (3.7) 0.678 (0.256–1.796)/0.434
C 0.821 0.822 0.983 -
T 0.179 0.178
Data are presented as number of carriers (%) or proportion of sample. The control group contained non-diabetic subjects and cases were type 2 diabetic patients.
*P values were computed using x2 tests to compare case and control groups.
{P values were computed using logistic regression analysis and are adjusted for age and gender.
doi:10.1371/journal.pone.0054259.t001
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Table S1 summarizes the characteristics of the 23 studies
included in the meta-analysis. Seven of these studies analyzed the
UCP1 -3826A/G polymorphism (3071 cases/2561 controls), 12
analyzed the UCP2 -866G/A polymorphism (4487/4229), 5
analyzed the UCP2 Ala55Val polymorphism (2112/1841), 3
analyzed the UCP2 Ins/Del polymorphism (1010/699), and 8
investigated the UCP3 -55C/T polymorphism (3370/3690).
Table S2 lists the genotype and allele distributions and OR
(95% CI) for the UCP polymorphisms in case and control samples
from the different studies reviewed.
Table S3 shows the quality of each individual study, assessed
using the NOS scale. The highest quality studies were awarded
nine stars. In general, most studies were considered as having good
quality selection, comparability and exposure. None of the studies
scored less than six stars and 47.8% of the studies had eight or nine
stars.
Quantitative synthesis. Table 2 summarizes the results of
the pooled analyses for associations between UCP polymorphisms
and susceptibility to T2DM. Gene-disease associations were
measured for the following genetic inheritance models: allele
contrast, additive, recessive, dominant and co-dominant. Figure 2
illustrates the pooled OR for the associations between T2DM and
UCP1 -3826A/G and UCP3 -55C/T polymorphisms and
Figure 3 illustrates the pooled OR for the associations between
the three UCP2 polymorphisms and T2DM, both assuming the
allele contrast model.
Our results revealed no significant associations between T2DM
and UCP1 -3826A/G, UCP2 -866G/A or UCP2 Ins/del
polymorphisms, irrespective of whether allele contrast, additive,
recessive, dominant or co-dominant models of inheritance were
used (Table 2). Furthermore, no significant associations were
found between these polymorphisms and T2DM when allele
contrast models were used after stratification for ethnicity
(Table 2).
The UCP2 Ala55Val polymorphism was significantly associated
with T2DM risk, but only when assuming a dominant inheritance
model (REM OR 1.27, 95% CI 1.03–1.57) (Table 2). Further-
more, stratification by ethnicity revealed that, assuming an allele
contrast model, the 55Val allele was significantly associated with
risk of T2DM in Asians (REM OR 1.25, 95% CI 1.02–1.51), but
not in Europeans (REM OR 0.90, 95% CI 0.63–1.27). When
assuming the dominant model, the 55Val allele was also associated
with risk of T2DM in Asians (REM OR 1.34, 95% CI 1.02–1.76).
The UCP3 -55C/T polymorphism was significantly associated
with T2DM when assuming allele contrast (REM OR = 1.17, 95%
CI 1.02–1.34), additive (REM OR = 1.32, 95% CI 1.01–1.72) or
dominant (REM OR = 1.18, 95% CI 1.02–1.37) models of
inheritance. Additionally, a marginally significant association with
T2DM was observed for the recessive (FEM OR = 1.11, 95% CI
1.00–1.24) and co-dominant (FEM OR = 1.05, 95% CI 1.00–1.10)
models. Stratification by ethnicity showed that, when assuming an
allele contrast model, the UCP3 -55T allele was associated with
T2DM in Asians (REM OR = 1.22, 95% CI 1.04–1.44) but not in
Europeans (REM OR = 1.12, 95% CI 0.91–1.38). In the same
way, when assuming a dominant model, this polymorphism was
associated with T2DM only Asians (REM OR = 1.28, 95% CI
1.06–1.55).
As can be observed in Table 2, there was significant
heterogeneity between studies investigating the UCP polymor-
phisms when assuming the allele contrast model for the whole
sample. Furthermore, significant heterogeneity was also observed
between studies when assuming some of the other models of
inheritance for these polymorphisms (I2.50%; Table 2). To
investigate this finding in greater depth, sex, age, BMI and
ethnicity were used as covariates in the meta-regression analyses
performed for the five UCP polymorphisms under different
inheritance models. None of the covariates used in univariate
meta-regression analyses could individually explain the heteroge-
neity observed (data not shown). Similarly, multivariate meta-
Figure 1. Flowchart illustrating the search strategy used to identify association studies of UCP1–3 polymorphisms and type 2
diabetes mellitus for the meta-analysis.
doi:10.1371/journal.pone.0054259.g001
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regression analyses performed using these covariates also failed to
explain the inter-study heterogeneity (data not shown).
Sensitivity analyses were carried out in order to estimate the
influence of each individual study on the meta-analysis results
obtained when assuming allele contrast inheritance models by
repeating the meta-analysis omitting a different study each time.
Our results showed that no individual study significantly
influenced the inter-study heterogeneity or the pooled ORs for
the UCP2 Ala55Val, UCP2 Ins/Del and UCP3 -55C/T polymor-
phisms (data not shown). In contrast, two studies [34,39] were
largely responsible for the heterogeneity observed in the meta-
analysis of UCP2 -866G/A polymorphism. Heterogeneity was
eliminated by exclusion of these two studies (I2 = 0% for the allele
contrast model), but this did not significantly change the pooled
OR (OR = 1.01, 95% CI 0.98–1.05). Similarly, heterogeneity
among studies of the UCP1 -3826A/G polymorphism was
effectively reduced (I2 = 32.7% for the allele contrast model) by
exclusion of one study [33] and the recalculated pooled OR almost
reached statistical significance (OR = 0.89, 95% CI 0.79–1.00).
No significant publication bias was detected in any of the
inheritance models assessed for any of the UCP polymorphisms
analyzed (Figures S1 and S2), which suggests that our data are
statistically robust.
Discussion
Uncoupling protein 1, UCP2 and UCP3 are regarded as
candidate genes for obesity and T2DM because they have been
found to decrease mitochondrial membrane potential and mediate
proton leak [9,47]. Mutations reducing the activity or expression
of these proteins could theoretically reduce energy expenditure by
increasing coupling of oxidative phosphorylation, thereby con-
tributing to the development of obesity and, consequently, T2DM.
Moreover, mutations in UCP2 regulatory regions leading to
increased expression could directly cause or exacerbate decreased
glucose-stimulated insulin secretion, because of a reduced ATP/
ADP ratio in pancreatic beta-cells and could therefore possibly
contribute to the development of T2DM [47]. These are the
reasons why the roles played by the UCP1 -3826A/G, UCP2 -
866G/A, UCP2 Ala55Val, UCP2 Ins/Del and UCP3 -55C/T
polymorphisms in T2DM risk have been studied extensively, but
the results of these association studies remain inconclusive
(reviewed in [3,4,5,6,9,47]). In an attempt to arrive at a more
definitive conclusion about the associations between UCP poly-
morphisms and T2DM, we performed a case-control study of a
Brazilian Caucasian population and a meta-analysis of genetic
association studies on the subject.
Our case-control study showed that the genotype and allele
frequencies of UCP1 -3826A/G, UCP2 -866G/A, UCP2 Ala55Val,
UCP2 Ins/Del and UCP3 -55C/T polymorphisms were similar in
T2DM patients and non-diabetic subjects, suggesting that these
polymorphisms are not important risk factors for T2DM in our
population. It is also worth mentioning that the frequencies of
these polymorphisms in our samples were similar to frequencies
observed in other Caucasian populations
[27,28,30,31,34,35,40,41,42,45].
Certain factors unrelated to the UCP polymorphisms could have
interfered with the findings of our case-control study. First, even
Figure 2. Forest plots showing individual and pooled ORs (95% CI) for the associations between the UCP1 -3826A/G and UCP3 -55C/
T polymorphisms and type 2 diabetes mellitus under an allele contrast inheritance model. The areas of the squares reflect the weight of
each individual study and the diamonds illustrate the random-effects summary ORs (95% CI). a European population; b Asian population; c Mixed
population.
doi:10.1371/journal.pone.0054259.g002
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though only Brazilian Caucasian subjects were studied, both
T2DM patients and nondiabetic subjects were recruited from the
same hospitals, and the OR obtained was adjusted for age and
gender, we cannot rule out the possibility of population
stratification bias when analysing our samples. Thus, our results
should be interpreted with caution since we did not estimate the
ancestral genetic background of our samples using genetic
markers, which would be the best way to exclude population
stratification bias due to ethnic admixture. Second, we cannot fully
exclude the possibility of type II error when analyzing associations
between the UCP polymorphisms and T2DM. Our statistical
power to detect an OR $1.4 was .80% for the UCP1 and UCP2
polymorphism, but was less than 80% for the UCP3 -55C/T
polymorphism due to the low frequency of the -55T allele. On the
other hand, our power was less than 80% for all UCP
polymorphisms when considering an OR of 1.14 (95% CI 1.12–
1.16), which is the mean OR obtained for the >20 genetic variants
so far consistently associated with risk of T2DM [48]. Moreover,
we did not take multiple testing corrections into account when
estimating the statistical power. Consequently, our power to detect
an association between the analyzed polymorphisms and T2DM
could be even smaller. Third, our non-diabetic subjects are
approximately 15 years younger than diabetic patients. Although,
we tried to minimize this problem adjusting OR by age and sex
and selecting a control group with a mean age similar to the mean
age at T2DM diagnosis of the diabetic sample, we cannot exclude
the possibility that this difference could have influenced our results
given that increasing age is an important risk factor for developing
T2DM. Notwithstanding these limitations, taking into account
that the frequencies of the UCP polymorphisms are very similar
between T2DM patients and non-diabetic subjects, it seems
unlikely that these variants could play an important role in the
pathogenesis of T2DM in our population.
Meta-analysis has been considered a powerful tool for pooling
the results from different studies that can overcome the problem of
small sample sizes as well as inadequate statistical power of genetic
association studies of complex traits [49]. Therefore, to further
investigate the effects of the UCP1 -3826A/G, UCP2 -866G/A,
UCP2 Ala55Val, UCP2 Ins/Del and UCP3 -55C/T polymor-
phisms on T2DM susceptibility, we conducted a meta-analysis of
22 published articles from different populations and also included
the results from our case-control study. The results suggest that
UCP1 -3826A/G, UCP2 -866G/A and UCP2 Ins/Del polymor-
phisms are not associated with risk of T2DM in the populations
investigated. In contrast, when evaluating allele contrast and
dominant models, the UCP2 55Val allele was associated with
increased risk of T2DM in Asian samples but not in Europeans.
Furthermore, the UCP3 -55T allele also was associated with risk to
T2DM in Asian populations under allele contrast and dominant
models.
Figure 3. Forest plots showing individual and pooled ORs (95% CI) for the associations between the UCP2 -866G/A, Ala55Val and
Ins/Del polymorphisms and type 2 diabetes mellitus under an allele contrast inheritance model. The areas of the squares reflect the
weight of each individual study, and the diamonds illustrate the random-effects summary ORs (95% CI). a European population; b Asian population; c
Mixed population.
doi:10.1371/journal.pone.0054259.g003
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Subjects carrying the Val/Val genotype of the UCP2 Ala55Val
polymorphism appear to have a lower degree of uncoupling of the
mitochondrial internal membrane, lower energy expenditure [50],
higher exercise energy efficiency [51], higher metabolic rate,
increased susceptibility to obesity and T2DM [16,45,52,53] and
greater weight loss [54] than subjects with the Ala allele.
Notwithstanding, other studies have reported that this polymor-
phism is not individually associated with basal metabolic rate,
metabolic syndrome, BMI, obesity, insulin secretion or T2DM
[27,35,38,55,56,57,58]. The T allele of the UCP3 -55C/T
polymorphism has been associated with increased incidence of
T2DM [59], higher BMI [60,61], lower BMI [62,63], higher HDL
cholesterol levels [62], larger waist circumference [64], and high
total cholesterol and LDL cholesterol levels and reduced risk of
Table 2. Pooled measures for associations between the UCP1 -3826A/G, UCP2 -866G/A, UCP2 Ala55Val, UCP2 Ins/Del and UCP3 -
55C/T polymorphisms and susceptibility to T2DM.
Inheritance model n studies n cases n controls I2 (%) Pooled OR (95% CI)
UCP1 -3826A/G
Allele contrast overall 7 3,071 2,561 58.0 0.93 (0.82–1.06)
Allele contrast Asian 2 1,130 1,240 81.6 0.99 (0.74–1.33)
Allele contrast European 4 1,391 1,085 10.5 0.98 (0.85–1.14)
Additive 7 3,071 2,561 55.8 0.88 (0.66–1.16)
Recessive 7 3,071 2,561 44.5 0.94 (0.88–1.01)
Dominant 7 3,071 2,561 34.7 0.96 (0.91–1.00)
Co-dominant 7 3,071 2,561 0.0 0.99 (0.94–1.04)
UCP2 -866G/A
Allele contrast overall 12 4,487 4,229 54.8 1.03 (0.93–1.14)
Allele contrast Asian 4 1,159 1,300 0.0 0.97 (0.86–1.09)
Allele contrast European 7 2,788 2,271 70.9 1.03 (0.87–1.22)
Additive 11 4,356 4,111 49.0 1.02 (0.96–1.09)
Recessive 11 4,356 4,111 42.1 1.02 (0.96–1.08)
Dominant 11 4,356 4,111 54.4 1.01 (0.87–1.17)
Co-dominant 11 4,356 4,111 46.2 1.01 (0.97–1.05)
UCP2 Ala55Val
Allele contrast overall 5 2,243 1,959 93.4 1.09 (0.89–1.34)
Allele contrast Asian 3 1,197 1,270 86.5 1.25 (1.02–1.51)
Allele contrast European 2 915 571 97.5 0.90 (0.63–1.27)
Additive 4 1,981 1,723 79.5 1.41 (0.92–2.16)
Recessive 4 1,981 1,723 80.9 1.24 (0.82–1.87)
Dominant 4 1,981 1,723 61.4 1.27 (1.03–1.57)
Co-dominant 4 1,981 1,723 43.2 1.06 (1.00–1.12)
UCP2 Ins/Del
Allele contrast overall 3 1,010 699 44.6 1.01 (0.95–1.08)
Allele contrast European * 2 910 579 68.3 1.12 (0.77–1.63)
Additive 2 879 581 0.0 0.96 (0.84–1.11)
Recessive 2 879 581 0.0 0.96 (0.84–1.09)
Dominant 2 879 581 0.0 1.00 (0.92–1.09)
Co-dominant 2 879 581 0.0 1.02 (0.94–1.11)
UCP3 -55C/T
Allele contrast overall 8 3,370 3,695 63.1 1.17 (1.02–1.34)
Allele contrast Asian 2 986 1,051 76.0 1.22 (1.04–1.44)
Allele contrast European 5 1,839 2,195 59.7 1.12 (0.91–1.38)
Additive 8 3,370 3,695 54.1 1.32 (1.01–1.72)
Recessive 8 3,370 3,695 44.5 1.11 (1.00–1.24)
Dominant 8 3,370 3,695 54.8 1.18 (1.02–1.37)
Co-dominant 8 3,370 3,695 9.5 1.05 (1.00–1.10)
Where significant heterogeneity was detected (I2.50%), the DerSimonian and Laird random effect model (REM) was used to calculate OR (95% CI) for each individual
study and for the pooled effect; where heterogeneity was not significant, the fixed effect model (FEM) was used for this calculation.
*Stratification analysis was only performed for Europeans for the UCP2 Ins/Del polymorphism (allele contrast model), since only one study of Asians was identified.
doi:10.1371/journal.pone.0054259.t002
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T2DM [31]. However, other studies have not found associations
between this polymorphism and metabolic rate, obesity, BMI,
insulin secretion or T2DM [55,57,65,66,67]. The inconsistencies
in the results reported by the studies cited here may be at least
partially explained by differences in study design, sample size,
ethnicity, age, sex and environmental factors and also by
synergetic effects with other polymorphisms in the UCP genes
and in other genes associated with T2DM and/or obesity.
It is well known that functional polymorphisms can influence
gene expression, regulating the final quantity of protein in a given
tissue, or promote changes in protein activity. The -55C/T
polymorphism is located 55 bp upstream of the most commonly
used transcription initiation site of skeletal muscle [68]. This
polymorphism is potentially interesting because it is located at
6 bp from the TATA box and 4 bp downstream of a putative
peroxisome proliferator-activated receptor (PPAR) responsive
element and could modify the PPAR responsiveness of the
UCP3 gene [69,70]. For this reason, it has been suggested that
the UCP3 gene could be one of the PPAR-c targets involved in the
modulation of lipid metabolism and insulin sensitivity [63]. In
male Pima Indians, subjects carrying the -55T allele had
significantly higher UCP3 mRNA expression than homozygotes
for the -55C allele [71]. Moreover, reduced muscle UCP3 mRNA
levels have been associated with increased BMI in Pima Indians
[72]. The increased UCP3 mRNA expression in -55T allele
carriers could explain the association between this polymorphism
and lower BMI [62,63]; however, as already mentioned, other
studies have reported an association between this polymorphism
and higher BMI [60,61]. Further studies are still needed to
elucidate the functional effects of the UCP3 -55C/T polymor-
phism on UCP3 expression.
The UCP2 Ala55Val polymorphism causes a conservative
amino acid change (alanine/valine) at position 55 of exon 4 and,
until now, there had been no evidence that this alteration
generates a functional change in the protein [5]. It is therefore
possible that this polymorphism may not be a true disease-causing
variant, but could simply be reflecting the effects of a functional
polymorphism. Taking into account that the Ala55Val polymor-
phism is tightly linked to the UCP2 -866G/A polymorphism
(|D9| = 0.991) [17], which has a demonstrable effect on UCP2
gene expression in a number of different tissues (reviewed in [4,5]),
one could hypothesize that the -866G/A polymorphism should be
the candidate for the functional polymorphism in the UCP2 gene.
However, our meta-analysis results did not detect any association
between the UCP2 -866G/A polymorphism and T2DM; ruling
out a role in T2DM in the populations analyzed. Some other,
currently unknown, UCP2 causative polymorphisms in linkage
disequilibrium with the UCP2 Ala55Val polymorphism must be
responsible for the associations reported.
Despite all our efforts, we are aware that certain factors
unrelated to the UCP polymorphisms analyzed could have
interfered with the findings of our meta-analysis. First, meta-
analysis is notoriously prone to publication bias, and although we
have attempted to trace unpublished observations, we cannot be
sure that small negative studies were overlooked. Second, one of
the studies identified [57] was not included in the meta-analysis
because genotype and allele frequencies for the UCP2 Ala55Val,
UCP2 -866G/A and UCP3 -55C/T polymorphisms were not
reported for incident diabetic cases and were not provided by the
authors. Hsu et al. [57] analyzed 14 tag SNPs of the UCP2-UCP3
cluster in an ethnically diverse cohort of postmenopausal women
aged .50 years and showed that none of the polymorphisms
analyzed remained significantly associated with risk of T2DM
after adjustment for multiple testing. Notwithstanding, they
reported that a UCP2-UCP3 haplotype (rs591758–rs668517–
rs647126–rs1800006) was significantly associated with a greater
risk of T2DM especially among overweight Caucasians. This
haplotype was not constituted by any of the polymorphisms
evaluated in our study. Third, because of the difficulty in getting
the full texts of articles published in several languages, we only
included studies published in English and Spanish. Fourth,
heterogeneity is potentially a significant problem when interpret-
ing the results of any meta-analysis of genetic association studies,
and our meta-analysis showed significant inter-study heterogeneity
in almost all genetic inheritance models tested. To investigate this
issue in greater depth, meta-regression analyses were performed
and showed that age, sex, BMI, and ethnicity did not made
significant contributions to inter-study heterogeneity. The hetero-
geneity observed could be due to differences in sample selection,
genotyping methods or gene-environment interactions and with-
out detailed information on the metabolic and clinical character-
istics of the studies reviewed we could not fully exclude the
possibility that the heterogeneity observed might reduce our power
to detect true associations. However, sensitivity analyses omitting
one study at time did not significantly change the results for
associations between the UCP polymorphisms and T2DM. Fifth,
we also cannot rule out the possibility of type II error when
analyzing associations between the UCP polymorphisms and
T2DM after stratifying by ethnicity. For the whole sample, we
had at least 80% power (a= 0.05) to detect even modest ORs
(1.17–1.2) for almost all analyzed polymorphisms under the allele
contrast model, which is an evidence that our results are robust.
However, after stratification by ethnicity, we had 80% power to
detect only OR $1.3 for all UCP polymorphisms (allele contrast
model).
It is worth noting that our results are consistent with a previous
meta-analysis conducted by Xu et al. [73], who analyzed
associations between T2DM and UCP2 Ala55Val, UCP2 -866G/
A and UCP3 -55C/T polymorphisms in 17 studies, but did not
analyze neither the UCP1 -3826A/G and UCP2 Ins/Del
polymorphisms nor the allele contrast or co-dominant inheritance
models. These authors also failed to detect an association between
the UCP2 -866G/A polymorphism and T2DM. In common with
our meta-analysis, they also reported that the UCP3 -55C/T
polymorphism was associated with T2DM in Asians when
assuming an additive inheritance model (OR = 1.15; 95% CI
1.03–1.28), and in the overall population when assuming
dominant (OR = 1.33; 95% CI 1.02–1.73) and recessive
(OR = 1.19; 95% CI 1.04–1.36) models. Similarly, they found
that the UCP2 Ala55Val polymorphism was associated with
T2DM in Asians for the additive model (OR = 1.23; 95% CI
1.12–1.36), and in the overall population for dominant
(OR = 1.42; 95% CI 1.10–1.84) and recessive (OR = 1.39; 95%
CI 1.16–1.66) models.
The association between the UCP2 Ala55Val and UCP3 -55C/
T polymorphisms with T2DM only in Asian populations may be
explained in part by the known differences in lifestyle and body
weight distributions between Asian and Caucasian populations as
well as differences in the genotype frequencies of the analyzed
polymorphisms. Luan et al. [74] found that the effects of genetic
polymorphisms on obesity and related-diseases could be changed
by nutritional characteristic of the population. It may be possible
that different diet pattern between Caucasian and Asian popula-
tions could modulate the effect of UCP polymorphism on obesity
and diabetes susceptibility.
In conclusion, our results indicate that the UCP1 -3826A/G,
UCP2 Ins/Del and UCP2 -866G/A polymorphisms are not
important risk factors for T2DM. However, our results strongly
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suggest that the UCP2 Ala55Val and UCP3 -55C/T are associated
with susceptibility to T2DM, mainly in the Asian population. The
absence of any associations of the five UCP polymorphisms and
T2DM in our case-control study is in agreement with our meta-
analysis results showing important associations of the UCP2
Ala55Val and UCP3 -55C/T polymorphisms with T2DM only
in Asians. Further additional studies with larger samples are
necessary to elucidate the roles possibly played by UCP
polymorphisms in the pathogenesis of T2DM; particularly studies
that analyze the effects of gene-gene and gene-environment
interactions.
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